N Visit www.newlimit.com →
Founded2021
HQSan Francisco, California
Categorylongevity biotech
The lenses
Scored on its own merits — not rolled up from the finds we publish.
Novelty 3
Impact · breadth 3
Impact · depth 4
Actionable 1
Substance 3
Hype 3
Related concepts
Appears in finds
Top 5 · NewLimit
Lens
Window
Theme
Overall = breadth + depth + substance + ½·novelty + freshness (a small boost that halves each week)
01 
02 
See the full feed → demoLongevity & Health
NewLimit
Brian Armstrong's longevity company raised $435M and pulled its first reprogramming drug — aimed at alcohol-damaged livers — forward from a decade out to a 2027 trial filing.
Overall▄▄▄▂▅▄high · first-partyNewLimit
paperLongevity & Health
A decade to next year
NewLimit just raised $435 million at a $3.1 billion valuation to reverse cellular aging — tripling its worth in a year on a prototype drug that has never touched a human and whose results it has not published.
Overall▄▃▄▂▄▃high · first-partyNewLimit
No finds in this window — widen it to see more.
How this connects
Tap a node to open it
NewLimitLongevity & HealthBiotech & Synthetic BiologyNewLimitA decade to next yearEpigenetic reprogrammingAI drug discoveryArtificial IntelligenceHuman EnhancementDemis HassabisJennifer DoudnaEli LillyAlphabetJ. Craig Venter InstituteBrian ArmstrongThe edit that lowers cholesterolInsilico MedicineVERVE-102Verve TherapeuticsThe chromosomes stayed wholeCRISPR that makes its own couriersUnited Therapeutics